Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

January 19, 2011 By Bio-Medicine.Org

CAMBRIDGE, Mass., Jan. 19, 2011 /PRNewswire/ — Pervasis
Therapeutics, Inc. today announced that the company is pursuing a
matrix-embedded endothelial cell-based therapy (PVS-30200) to
target and regulate cell stroma (the tumor environment or
“ecosystem” that is comprised of various supporting cell types
distinct from cancer cells) in order to prevent key processes that
play a role in advancing solid tumor growth and metastasis (the
spread of cancer cells to secondary locations). A cornerstone of
Pervasis’ oncology program, the company has entered into an
exclusive patent license agreement with the Massachusetts Institute
of Technology (MIT) for all discovery and development activities
associated with cellular implants for cancer diagnosis, prognosis
and treatment. In addition, supportive evidence from multiple
preclinical studies demonstrates the powerful anti-angiogenic,
anti-proliferative and anti-inflammatory properties of this
endothelial cell-based approach in the presence of various solid
tumor cancers, such as brain, lung, breast and prostate.

Pervasis, a clinical stage company based in Cambridge, Mass., is
focused on developing breakthrough cell-based therapies that
harness the healing power of the endothelium, the thin layer of
cells that lines the interior surface of every blood vessel in the
body. The company’s other areas of clinical investigation include
improving outcomes following common vascular surgical and
interventional procedures, such as hemodialysis access,
angioplasties, stents and peripheral and coronary bypass grafts —
the failures of which result in serious complications and a
significant increase in medical costs.

“We are very excited to expand our focus to include the critical
area of oncology,” stated Frederic Chereau, president and chief
executive officer of Pervasis. “We already have amassed a
significant amount of data demonstrating the safety and efficacy of
utilizing our novel cell-based approach to improve outcom

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech